Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
Credit agrmnt [a]
|
|
Gossamer Bio, Inc. (GOSS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/20/2023 |
8-K
| Quarterly results |
| 12/06/2022 |
8-K
| Quarterly results |
| 10/13/2020 |
8-K
| Quarterly results |
| 05/14/2019 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of March 31, 2019, were $481.2 million. The Company expects current cash, cash equivalents and marketable securities, and access to its debt facility will be sufficient to fund its operating and capital expenditures into the second half of 2021. • Research and Development Expenses: For the quarter ended March 31, 2019, R&D expenses were $25.0 million, including $1.3 million of stock-based compensation, compared to R&D expenses of $2.6 million for the quarter ended March 31, 2018. The increase was primarily due to costs related to the research and development of GB001, GB002 and GB004. • In-Process Research and Development Expenses: For the quarter ended March 31, 2019, IPR&D ...",
"Slide Presentation" |
|
|
|